after you join the study, you are assigned to one of two treatment groups. one group receives the test combination called cevostamab plus pomalidomide and dexamethasone. the other group receives the standard of care, which may include medicines such as elotuzumab, carfilzomib, daratumumab, and dexamethasone.

your baseline health information, including blood tests and a bone‑marrow sample, is collected before treatment begins.

a bone‑marrow aspirate is performed to evaluate disease status using next‑generation sequencing. this provides the reference for later mr d‑negative cr assessments.

additional laboratory tests, vital‑sign measurements, and questionnaires about symptoms and quality of life are completed.

if you are in the test group, you begin receiving cevostamab by iv infusion. the medication is given as a concentrate that is mixed with a solution and delivered through a needle in a vein.

you also start oral pomalidomide tablets and oral or iv infusion dexamethasone, according to the study schedule.

if you are in the standard‑of‑care group, you receive the assigned medicines (for example, elotuzumab or carfilzomib by iv infusion, daratumumab by subcutaneous injection, and dexamethasone by oral or iv infusion) as described in the protocol.

treatment is given in repeated cycles. each cycle includes the scheduled doses of the study drugs and may last several weeks, as defined by the protocol.

the same medicines are taken in each cycle unless a dose adjustment is required because of side effects.

during each cycle you attend clinic visits for safety monitoring. blood samples are drawn to check blood counts, organ function, and drug levels.

your doctor evaluates any side effects using standardized grading systems. dose interruptions, reductions, or discontinuation may be recommended based on these evaluations.

periodic imaging or bone‑marrow assessments are performed to track disease response, including a scheduled mr d‑negative cr assessment at 9 months.

responses are classified using criteria such as complete response, very good partial response, partial response, and stable disease. these are determined by the independent review committee.

if a response is achieved, the time to first response and the depth of response are recorded.

treatment continues until disease progression, unacceptable toxicity, or completion of the planned number of cycles, as defined by the study.

if disease progression is observed or if serious side effects occur, treatment may be stopped and subsequent care is arranged.

after stopping study medication, you enter a follow‑up period. periodic visits are scheduled to monitor long‑term safety, survival, and disease status.

follow‑up assessments may include blood tests, imaging, and questionnaires about symptoms and quality of life.